Renaissance Technologies
PMCB icon

Renaissance Technologies’s PharmaCyte Biotech PMCB Stock Holding History

Renaissance Technologies’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.3K Sell
37,987
-18,513
-33% -$13.9K ﹤0.01% 3076
2026
Q1 		$37.6K Sell
56,500
-37,536
-40% -$28.7K ﹤0.01% 3127
2025
Q4 		$68.1K Buy
94,036
+14,036
+18% +$12.6K ﹤0.01% 3059
2025
Q3 		$77.6K Buy
80,000
+30,200
+61% +$30.1K ﹤0.01% 3289
2025
Q2 		$54.3K Buy
49,800
+300
+0.6% +$335 ﹤0.01% 3383
2025
Q1 		$61.9K Buy
49,500
+200
+0.4% +$325 ﹤0.01% 3268
2024
Q4 		$77.4K Sell
49,300
-400
-0.8% -$690 ﹤0.01% 3320
2024
Q3 		$94.9K Buy
49,700
+1,200
+2% +$2.23K ﹤0.01% 3266
2024
Q2 		$95.1K Buy
48,500
+4,700
+11% +$10.1K ﹤0.01% 3192
2024
Q1 		$104K Buy
43,800
+5,700
+15% +$12.3K ﹤0.01% 3360
2023
Q4 		$82K Buy
38,100
+5,200
+16% +$11.3K ﹤0.01% 3353
2023
Q3 		$69K Buy
32,900
+7,026
+27% +$17.9K ﹤0.01% 3330
2023
Q2 		$74K Buy
+25,874
New +$77.6K ﹤0.01% 3535

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Renaissance Technologies's PMCB Position: Q2 2026 in Review

Renaissance Technologies reduced its PharmaCyte Biotech (PMCB) stake by 33% in Q2 2026, selling an estimated $13.9K and leaving 37,987 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3076.

Renaissance Technologies first reported a position in PMCB in Q2 2023 and has held it in 13 quarters since. The position peaked at $104K in Q1 2024. 19 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Renaissance Technologies held 37,987 shares of PharmaCyte Biotech worth $29.3K as of Q2 2026.
  • Renaissance Technologies sold 18,513 PharmaCyte Biotech shares in Q2 2026, an estimated $13.9K.
  • PharmaCyte Biotech made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3076 holding.
  • Renaissance Technologies first reported a position in PharmaCyte Biotech in Q2 2023 and has held it in 13 quarters since.
  • Renaissance Technologies's PharmaCyte Biotech position peaked at $104K in Q1 2024.
  • 19 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.